Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.04.1714
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2018
Authors
Publisher
Elsevier BV